Curza, founded with a mission to combat infectious diseases and cancer, is a small-molecule therapeutics company. The company has developed several structurally distinct classes of proprietary drugs, with a primary focus on creating new classes of broad-spectrum antibiotics targeting ESKAPE pathogens and drug-resistant Gram-negative bacteria. Curza aims to address the global health crisis of antibiotic resistance through innovative pharmaceutical solutions.
Notable affiliated individuals and investors include key figures in the biotechnology and pharmaceutical industries, though specific names are not provided. Curza's significant achievements include the development of novel antibiotics that have the potential to save lives by addressing the urgent need for effective treatments against resistant bacterial infections. The company's impact is marked by its contribution to global health, particularly in the fight against antibiotic resistance and cancer.
